V5 Ultimate
Ultimate
PricingResourcesCompany
English (original)العربيةDeutschΕλληνικάEspañolFrançaisItalianoעברית日本語한국어NederlandsPolskiPortuguêsSvenska
Talk to us Log in Start free trial
Food & Beverage
  • Bakery & Confectionery
  • Food Processing
  • Ingredients & Dry Mixes
  • Sausage & Meat Products
  • Produce Packing
  • Pet Food & Pet Supplements
  • Dairy & Chilled Foods
  • Beverages & Liquid Manufacturing
  • Infant Formula
Pharma & Life Sciences
  • Radiopharmaceuticals
  • Pharmaceutical
  • Medical Devices
  • Veterinary Pharmaceuticals
  • Blood & Tissue
  • Diagnostics & IVD Kits
  • Reference Materials & Standards
  • OTC Topical Creams & Gels
Supplements & Personal Care
  • Dietary Supplements
  • Cosmetics & Personal Care
  • Cannabis & Hemp Manufacturing
  • Fragrances & Perfumery
  • Soaps & Personal Hygiene
  • Botanical Extracts & Essential Oils
Chemicals & Materials
  • Plastics & Resins
  • Agricultural Chemicals
  • Specialty & Industrial Chemicals
  • Printing Inks, Pigments & Construction Chemicals
  • Lubricants & Metalworking Fluids
  • Coatings, Adhesives & Sealants
Other Manufacturing
  • Consumer Products
  • Electronics & Electrical Assembly
  • Textiles & Nonwoven
  • Contract Manufacturing & Co-Packing
  • Packaging & Food-Contact Materials
  • Regulated Warehousing & Distribution
Explore all industries
  • Warehouse & TraceabilityReceive, store, pick and trace
  • Production & PlanningPlan jobs and guide production
  • Quality & LaboratoryTest, investigate and review
  • Documents & TrainingControl procedures and qualifications
  • Equipment & PerformanceMaintain assets and measure losses
  • Orders & IntegrationsConnect customers, suppliers and systems
  • Outputs & InsightsReports, KPIs and label design
Why V5? Product & Features
Why V5?Product & Features
  • Warehouse & TraceabilityReceive, store, pick and trace
  • Production & PlanningPlan jobs and guide production
  • Quality & LaboratoryTest, investigate and review
  • Documents & TrainingControl procedures and qualifications
  • Equipment & PerformanceMaintain assets and measure losses
  • Orders & IntegrationsConnect customers, suppliers and systems
  • Outputs & InsightsReports, KPIs and label design
Explore all industries
    • Bakery & Confectionery
    • Food Processing
    • Ingredients & Dry Mixes
    • Sausage & Meat Products
    • Produce Packing
    • Pet Food & Pet Supplements
    • Dairy & Chilled Foods
    • Beverages & Liquid Manufacturing
    • Infant Formula
    • Radiopharmaceuticals
    • Pharmaceutical
    • Medical Devices
    • Veterinary Pharmaceuticals
    • Blood & Tissue
    • Diagnostics & IVD Kits
    • Reference Materials & Standards
    • OTC Topical Creams & Gels
    • Dietary Supplements
    • Cosmetics & Personal Care
    • Cannabis & Hemp Manufacturing
    • Fragrances & Perfumery
    • Soaps & Personal Hygiene
    • Botanical Extracts & Essential Oils
    • Plastics & Resins
    • Agricultural Chemicals
    • Specialty & Industrial Chemicals
    • Printing Inks, Pigments & Construction Chemicals
    • Lubricants & Metalworking Fluids
    • Coatings, Adhesives & Sealants
    • Consumer Products
    • Electronics & Electrical Assembly
    • Textiles & Nonwoven
    • Contract Manufacturing & Co-Packing
    • Packaging & Food-Contact Materials
    • Regulated Warehousing & Distribution
PricingResourcesCompany
Start free trial Log in Talk to us
HomeGlossaryAnnex 13
Compliance · The complete guide

Annex 13EU GMP Annex 13 — Investigational Medicinal Products

In short

Annex 13 is the EudraLex Volume 4 guideline for manufacturing, labelling, and releasing Investigational Medicinal Products — and in the EU it has been layered over, for clinical trials run under Regulation (EU) 536/2014, by a dedicated Commission Delegated Regulation.

3,139 words · ~15 min read
Trial supply coordinator in full protective clothing checks labelled investigational packs on shelving with a tablet
Annex 13 covers making, blinding, labelling and releasing investigational medicinal products. Editorial illustration; not a customer photograph.
On this page
  1. 01Where Annex 13 sits in EudraLex Volume 4
  2. 02Manufacturing and authorisation of IMPs
  3. 03Labelling requirements for blinded trials
  4. 04Randomisation and unblinding controls
  5. 05Release by a Qualified Person and the two-step release concept
  6. 06Comparator products and blinding/packaging operations
  7. 07Reconciliation, destruction and record retention
  8. 08Relationship to the EU Clinical Trials Regulation 536/2014
On this page · 8 sections
  1. 1Where Annex 13 sits in EudraLex Volume 4
  2. 2Manufacturing and authorisation of IMPs
  3. 3Labelling requirements for blinded trials
  4. 4Randomisation and unblinding controls
  5. 5Release by a Qualified Person and the two-step release concept
  6. 6Comparator products and blinding/packaging operations
  7. 7Reconciliation, destruction and record retention
  8. 8Relationship to the EU Clinical Trials Regulation 536/2014
AI · Explain it for MY operation

How does Annex 13 apply to your shop floor?

Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.

Your scale

01Where Annex 13 sits in EudraLex Volume 4

EudraLex Volume 4 collects the European Commission's good manufacturing practice (GMP) guidelines for medicinal products for human and veterinary use. The main body of Volume 4 — Part I's basic requirements and Part II's requirements for active substances — is written for authorised, marketed medicinal products. Annex 13, Investigational Medicinal Products, is one of roughly twenty annexes that adapt or supplement those basic requirements for a specific product category or process, in this case a medicine that is still being tested in a clinical trial rather than sold under a marketing authorisation.

The version reviewed here was adopted by the European Commission on 31 January 2010 with a deadline for coming into operation of 31 July 2010, following public consultation between April 2008 and January 2009. Its stated Principle frames the whole annex: investigational medicinal products (IMPs) should be produced in accordance with the general GMP principles and detailed guidelines set out in Volume 4, with other Commission guidance taken into account as relevant to the stage of development, because manufacturing an IMP is inherently more variable and higher-risk than manufacturing an authorised product — there are no fixed routines, trial designs and packaging designs vary, and randomisation and blinding are frequently required.

Annex 13 explicitly scopes itself to the manufacturing side of a clinical trial and states that it also covers guidance on ordering, shipping, and returning clinical supplies, describing this guidance as being at the interface with, and complementary to, the separate body of Good Clinical Practice (GCP) requirements that govern how a trial is conducted at the investigator site. The annex distinguishes an investigational medicinal product from a non-investigational medicinal product (NIMP) — support or escape medication, or product used to induce a physiological response under the protocol — which falls outside Annex 13's scope even though it is supplied in connection with the same trial.

02Manufacturing and authorisation of IMPs

Annex 13 states that both the total and partial manufacture of IMPs, and the various processes of dividing up, packaging, or presentation, require the manufacturing authorisation referenced in the underlying EU legislation of the time (Article 13(1) of Directive 2001/20/EC, read with Article 9(1) of Directive 2005/28/EC). A narrow exception exists for reconstitution — understood as the simple process of dissolving, dispersing, diluting, or mixing the IMP with a vehicle solely for administration to a trial subject — which does not itself require a separate manufacturing authorisation, provided it does not amount to combining several ingredients, including the active substance, to produce the investigational product.

Annex 13 requires separation of production and quality control responsibilities for each batch, even where staffing is small enough that the same limited group handles multiple roles, and it asks the Qualified Person (QP) to have systems in place meeting GMP and a broad knowledge of pharmaceutical development and clinical trial processes. Documentation obligations are built around the Product Specification File — a living reference file, continually updated with traceability to prior versions, that gathers specifications and analytical methods, manufacturing methods, in-process testing, approved label copy, the relevant trial protocol and randomisation code, technical agreements, stability data, and storage/shipment conditions. The annex is explicit that this file forms the basis on which the QP assesses a batch's suitability for certification and release, and that where different manufacturing steps happen at different sites under different QPs, each may hold a file limited to its own scope of activity.

Because IMP specifications and processes evolve across a development program, Annex 13 requires that each new version of a specification or instruction take into account current data and technology, allow traceability to the version it replaces, and follow a written change procedure that specifically considers implications for product quality — such as stability or bioequivalence — and for any clinical trials already under way.

03Labelling requirements for blinded trials

Annex 13's labelling provisions (its Articles 26–30, summarised in the annex's Table 1) list the particulars that should appear on an IMP label unless their absence is justified — for example by use of a centralised electronic randomisation system. The list includes the sponsor's (or CRO's or investigator's) name, address, and telephone number as the contact for emergency unblinding; dosage form, route of administration, and quantity of dosage units (with name/identifier and strength/potency added for open trials); the batch and/or code number identifying contents and packaging operation; a trial reference code identifying the trial, site, investigator, and sponsor; the subject identification/treatment number and visit number where relevant; directions for use; the words 'For clinical trial use only' or equivalent; storage conditions; the period of use in month/year format; and a child-safety warning except where the product is not taken home.

These particulars must appear in the official language(s) of the country of use, on both primary and secondary packaging, with narrower exceptions set out for two packaging configurations: where a primary package travels together with secondary packaging that already carries the full particulars, the primary package needs only a reduced set (sponsor name, dosage form/route, batch/code number, trial reference code, and subject/treatment number); and where the primary packaging is too small to carry the full particulars — blister packs or small ampoules, for instance — a similarly reduced set must still appear on the primary pack itself, with the full particulars moved to an accompanying secondary pack.

Annex 13 also allows symbols or pictograms to clarify label content, and additional information, warnings, or handling instructions to be added, while requiring that any supplementary labelling applied for a trial with the characteristics described in the underlying directive (added for subject-safety or emergency-identification purposes, such as sponsor contact details and the trial reference code) should not obscure the original labelling it is layered onto.

04Randomisation and unblinding controls

The annex defines blinding as the deliberate disguising of the identity of an IMP in accordance with the sponsor's instructions, and unblinding as the disclosure of that identity — distinguishing single-blinding (subjects unaware) from double-blinding (subjects, investigators, monitors, and in some cases data analysts unaware). Where products are blinded, Annex 13 requires systems that achieve and maintain the blind while still allowing identification of blinded product when necessary, including traceability to the batch numbers assigned before the blinding operation, and requires that rapid identification remain possible in a genuine emergency.

Procedures must separately describe the generation, security, distribution, handling, and retention of any randomisation code used for packaging, together with the code-break mechanism for emergency unblinding, with appropriate records maintained throughout. Because blinded products of similar appearance are both more complex to package and harder to check visually than marketed product, Annex 13 calls for intensified precautions against mislabelling — label reconciliation, line clearance, and in-process control checks performed by appropriately trained staff — during packaging runs where more than one product may be on the same line at the same time.

De-coding arrangements for emergency unblinding must be available to the appropriate responsible personnel before IMPs are shipped to the investigator site, so that a code break can happen at the point of patient need without depending on the manufacturer's availability.

05Release by a Qualified Person and the two-step release concept

Annex 13 states that release of an IMP should not occur until the Qualified Person has certified that the relevant statutory requirements have been met, taking into account a non-exhaustive list of elements as appropriate to the specific circumstances: batch records (including control reports, in-process and release reports) demonstrating compliance with the Product Specification File, the order, the protocol, and the randomisation code, including all deviations and any consequent additional checks; production conditions; validation status of facilities, processes, and methods; examination of finished packs; post-importation analyses where relevant; stability reports; the source and verification of storage and shipment conditions; audit reports on the manufacturer's quality system; documentation of the manufacturer's authorisation to manufacture or export; applicable regulatory and GMP requirements and any official verification of compliance; and any other factor of which the QP is aware that is relevant to batch quality.

The QP's duties differ depending on the product's circumstances — product manufactured in the EU without an EU marketing authorisation, product sourced from the open EU market under an existing marketing authorisation (where certification scope can be narrowed to the blinding, trial-specific packaging, and labelling actually performed), product imported directly from a third country (where a Mutual Recognition Agreement, or in its absence the QP's own audit-based knowledge of the manufacturer's quality system, establishes GMP equivalence), and imported comparator product for which equivalent-GMP assurance cannot be obtained, each tied to a specific statutory duty. Where manufacturing and packaging happen at different sites under different QPs, Annex 13 points to the GMP guide's Annex 16 recommendations on QP certification and batch release across multiple sites.

The annex's shipping section sets out the two-step release concept directly: investigational medicinal products should remain under the sponsor's control until completion of a two-step procedure — certification by the Qualified Person, and separate release by the sponsor for use in the clinical trial once the conditions for commencing the trial under the underlying clinical-trials legislation have been fulfilled. Both steps should be recorded and retained in the sponsor's trial files, and the sponsor should maintain a change-control process — typically documented in a Technical Agreement between the QP and the sponsor — so that the Product Specification File the QP certified against stays aligned with what the competent authorities ultimately accepted for the trial.

A harmonised batch-certification format, intended to support movement of certified IMP batches between EU Member States, is provided as an attachment to the annex. Where local regulations permit packaging or labelling at the investigator site under a clinical trials pharmacist or other qualified healthcare professional, the QP is not required to certify that specific activity, but the sponsor remains responsible for ensuring it is documented and carried out to GMP principles, with the QP's advice sought as appropriate.

06Comparator products and blinding/packaging operations

Annex 13 defines a comparator product as an investigational or marketed product (an active control) or a placebo used as a reference in a trial. Comparator products raise distinct challenges because they may be sourced from the open market, repackaged, or relabelled to preserve the blind, and the manufacturer or importer handling that repackaging is undertaking GMP-regulated activity even though the comparator itself may already carry its own marketing authorisation elsewhere.

Where an imported comparator's GMP equivalence cannot be adequately assured through audit or a mutual recognition arrangement, Annex 13 directs that the QP's duty is defined by the relevant provision of the underlying directive specifically addressing that scenario, rather than by the general certification duty applied to EU-manufactured product. Design and equipment controls for blinding and packaging operations are tied to the same cross-contamination logic that runs through the annex: because the toxicity, potency, and sensitising potential of an IMP (and, by extension, of a comparator being handled alongside it) may not be fully understood, equipment design, premises, test methods, and post-cleaning acceptance limits should reflect that uncertainty, with campaign working considered where appropriate and cleaning-solvent choices informed by the product's solubility profile.

The product specification file's packaging documentation, the approved label copy, and the randomisation code together form the reference set against which a packaging and blinding operation — whether performed on the IMP itself or on a comparator being re-presented for the trial — is checked, and the annex expects that reference set to be available to the QP making the certification decision.

07Reconciliation, destruction and record retention

Annex 13's Recalls and Returns section requires sponsor-agreed procedures for retrieving IMPs and documenting that retrieval, with investigators and monitors understanding their obligations, and requires that any supplier of a comparator or other trial medication have a system for communicating recall needs to the sponsor. Returned IMPs must be returned on agreed conditions set out in approved written procedures, clearly identified, stored in an appropriately controlled dedicated area, with inventory records kept of the returned product.

The sponsor is responsible for destruction of unused or returned IMPs, and the annex states plainly that IMPs should not be destroyed without the sponsor's prior written authorisation. Delivered, used, and recovered quantities must be recorded, reconciled, and verified by or on behalf of the sponsor for each trial site and each trial period, and destruction of unused product for a given site or period may proceed only after any discrepancy in that reconciliation has been investigated, satisfactorily explained, and the reconciliation accepted. Destruction operations themselves must be recorded so that all operations can be accounted for, with the sponsor keeping the records; when destruction occurs, a dated certificate or receipt should be issued that clearly identifies, or allows traceability to, the batches and/or patient numbers involved and the quantities actually destroyed.

StageWho is responsibleCore record
OrderSponsor authorises; manufacturer executesWritten order referencing the Product Specification File and protocol
CertificationQualified PersonBatch certification against the Product Specification File
ReleaseSponsor, after QP certification and trial-commencement conditions are metTwo-step release record (certification + sponsor release)
ReturnSponsor-defined procedure; site/investigator executesInventory record of returned product
ReconciliationSponsor (or on its behalf)Delivered/used/recovered quantities reconciled per site and period
DestructionSponsor authorises; carried out only after reconciliation acceptedDated destruction certificate or receipt with batch/subject traceability

Annex 13 also requires that complaints which could arise from product quality be discussed between the manufacturer or importer and the sponsor where they differ, involving the QP and those responsible for the trial so the potential impact on trial subjects, product development, and the trial's data can be assessed — tying the quality complaint-handling process back into the same chain of accountability that runs through certification, release, and reconciliation.

08Relationship to the EU Clinical Trials Regulation 536/2014

The Annex 13 text reviewed above was adopted under the earlier Clinical Trials Directive (2001/20/EC) and its implementing Directive 2005/28/EC. The EU's Clinical Trials Regulation, Regulation (EU) No 536/2014, repealed that directive and became applicable across the EU on 31 January 2022, moving trial authorisation to a single EU portal and database (the Clinical Trials Information System). Article 63(1) of Regulation (EU) 536/2014 provides that IMPs must be manufactured applying good manufacturing practice to safeguard subject safety and the reliability of the trial data, and empowers the Commission to adopt delegated acts specifying the principles and guidelines for that GMP.

The Commission exercised that power through Commission Delegated Regulation (EU) 2017/1569 of 23 May 2017, which supplements Regulation (EU) 536/2014 by specifying GMP principles and guidelines for IMPs for human use and arrangements for inspections, and which became applicable from the date Regulation (EU) 536/2014 itself applied. The Commission also issued detailed guidelines, C(2017) 8179 final of 8 December 2017, under Article 63(1) of the Regulation, stating explicitly that they complement Delegated Regulation 2017/1569 and lay down tools — flexible enough to accommodate changes as process knowledge grows — to address issues specific to IMPs. For clinical trials falling within the scope of Regulation (EU) 536/2014, this delegated regulation and its accompanying Commission guidelines are therefore the current, directly applicable EU legal instruments governing IMP GMP, rather than the original EudraLex Annex 13 text, which was written against the Directive it has since been overtaken by for those trials.

The core requirements described in this article — manufacturing authorisation, the Product Specification File concept, blinded labelling particulars, randomisation and code-break control, two-step QP certification and sponsor release, and sponsor-led reconciliation and destruction — originate in Annex 13 and recur, in substance, in the 2017 delegated regulation and guidelines, because both instruments were written to the same underlying GMP objectives for trial product. A sponsor or manufacturer operating in the EU should confirm, for any specific trial, which instrument is the controlling legal text for that trial's authorisation pathway and jurisdiction, since EudraLex Annex 13 as a Commission GMP annex and the 2017 delegated regulation/guidelines are not drafted as a single consolidated document and a reader should not assume one has formally superseded the other in every respect without checking the current Commission guidance referenced from the EudraLex Volume 4 and Clinical Trials Regulation web pages.

Frequently asked questions

Q.Is EudraLex Annex 13 still the controlling EU text for IMP manufacturing?+

For clinical trials authorised under Regulation (EU) 536/2014, which became applicable across the EU on 31 January 2022, the directly relevant instruments are Commission Delegated Regulation (EU) 2017/1569 and the Commission's accompanying detailed guidelines (C(2017) 8179), both adopted under Article 63(1) of that Regulation. The original Annex 13 text was written against the earlier Clinical Trials Directive (2001/20/EC) framework. The substantive GMP expectations — manufacturing authorisation, the Product Specification File, blinded labelling, randomisation controls, QP certification, reconciliation, and destruction — carry through in substance, but a sponsor should confirm which instrument formally governs a specific trial and jurisdiction rather than citing Annex 13 alone.

Q.What is the 'two-step release' concept in Annex 13?+

Annex 13 requires that an investigational medicinal product remain under the sponsor's control until two separate steps are both complete: certification by the Qualified Person that the applicable GMP and regulatory requirements have been met, and a subsequent release decision by the sponsor confirming that the conditions for commencing the clinical trial have been fulfilled. Both steps must be recorded and retained in the sponsor's trial files; completing certification alone does not authorise use of the product in the trial.

Q.What must appear on a blinded IMP label?+

Annex 13 lists particulars including the sponsor/CRO/investigator contact for emergency unblinding, dosage form and route of administration, the batch and/or code number, a trial reference code, the subject identification/treatment number, directions for use, 'For clinical trial use only' wording, storage conditions, and the period of use — unless an item's absence is specifically justified, for example by use of a centralised electronic randomisation system. Reduced particulars apply to small primary packaging such as blister packs or ampoules, provided the full particulars appear on accompanying secondary packaging.

Q.Who is responsible for destroying unused investigational product?+

The sponsor is responsible for destruction of unused or returned IMPs, and Annex 13 states that IMPs should not be destroyed without the sponsor's prior written authorisation. Destruction of unused product for a given trial site or period may only proceed after delivered, used, and recovered quantities have been reconciled and any discrepancy has been investigated and satisfactorily explained. A dated destruction certificate or receipt, with traceability to the relevant batches or patient numbers, should be produced and retained by the sponsor.

Q.Does Annex 13 cover comparator products as well as the test product?+

Annex 13 defines a comparator product as an investigational or marketed product, or a placebo, used as a reference in a trial, and addresses it specifically because comparators are frequently sourced, repackaged, or relabelled to maintain the blind. Where an imported comparator's GMP equivalence cannot be adequately assured, the Qualified Person's certification duty is defined by a specific provision of the underlying clinical-trials legislation rather than by the general certification duty that applies to EU-manufactured product.

Primary sources

  • EudraLex Volume 4, Annex 13 — Investigational Medicinal Products (health.ec.europa.eu, adopted 31 Jan 2010) — reviewed 9 Oct 2026
  • Regulation (EU) No 536/2014 on clinical trials (EUR-Lex) — reviewed 9 Oct 2026
  • Commission Delegated Regulation (EU) 2017/1569 — GMP for investigational medicinal products (EUR-Lex) — reviewed 9 Oct 2026
  • European Commission, Clinical trials — Regulation (EU) No 536/2014 overview page (health.ec.europa.eu) — reviewed 9 Oct 2026
  • European Commission, EudraLex — Volume 4 overview page (health.ec.europa.eu) — reviewed 9 Oct 2026

Further reading

  • QP Release
    The Qualified Person certification step that Annex 13 ties to the two-step release procedure.
  • Annex 16 — QP certification and batch release
    Multi-site QP certification principles Annex 13 points to when manufacturing and packaging are split across sites.
  • Annex 1 — Sterile Medicinal Products
    Related EU GMP annex for sterile manufacturing, relevant where an IMP is a sterile product.
  • 21 CFR Part 11
    The US electronic-records framework referenced alongside Annex 13 for IMP record-keeping systems.
  • Independent Part 11 Assessment
    Third-party review of V5 Ultimate's electronic-record and signature controls, relevant to IMP batch and randomisation records.
  • V5 Ultimate for Pharmaceutical — Overview
    General pharmaceutical manufacturing overview; does not describe IMP-specific or clinical-trial functionality.
Software that covers Annex 13
V5 Ultimate (GMP)
V5 Ultimate is a full-lifecycle GMP platform for US and international manufacturers — cGMP under 21 CFR 210/211, EU GMP Parts…
Talk to us about Annex 13

Want to see how Annex 13 could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.

Start free
Back to glossary
Where this term comes up
PharmaceuticalVet Pharma
Inside V5
  • → eBMR / eDHR — the batch record fills in as the work is done.
  • → 21 CFR Part 11 — signatures and audit history your team can validate.
  • → Document control — one version in force, every change signed and explained.
Example reports
V5Ultimate

Sample report

Electronic Batch Manufacturing Record (eBMR)

Plan & make

Electronic Batch Manufacturing Record (eBMR)View on screen or print
V5Ultimate

Sample report

Electronic Device History Record (eDHR)

Plan & make

Electronic Device History Record (eDHR)View on screen or print
V5Ultimate

Sample report

Compliance Readiness Assessment

Quality system

Compliance Readiness AssessmentView on screen or print
V5Ultimate

Sample report

Validation Support Pack

Quality system

Validation Support PackView on screen or print
→ All example reports
Regulatory anchors
  • EU GMP Annex 13
Related terms
  • → QP Release
  • → Annex 1
  • → EU Annex 11
  • → 21 CFR Part 11

Next Step

Try V5 with your own records, or ask a question first. Ask V5 opens with an editable question; nothing is sent until you choose to.

Start your free trial Browse All Features

Showing the site for the United States. Local spelling, dates and prices are applied automatically; change the language at the top of the page.

V5 Ultimate
Ultimate

Warehouse, quality and manufacturing software for regulated operations.

ProductIndustriesPricingResourcesSecurity & TrustCompanyLegal Centre

© S.G. Systems, LLC